SonoThera Raises $125 Million for Ultrasound-Delivered Genetic Medicines
The biotechnology company plans to move nonviral treatments for Duchenne muscular dystrophy and polycystic kidney disease toward clinical testing.
Archive
The biotechnology company plans to move nonviral treatments for Duchenne muscular dystrophy and polycystic kidney disease toward clinical testing.
Brett Adcock's new lab reached a $6 billion post-money valuation before releasing its first products to the public.